Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H19N3O3 |
| Molecular Weight | 289.3297 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(NC(=O)[C@H](N)CC1=CNC2=C1C=CC=C2)C(O)=O
InChI
InChIKey=SHAXSXUDZJSSCN-LLVKDONJSA-N
InChI=1S/C15H19N3O3/c1-15(2,14(20)21)18-13(19)11(16)7-9-8-17-12-6-4-3-5-10(9)12/h3-6,8,11,17H,7,16H2,1-2H3,(H,18,19)(H,20,21)/t11-/m1/s1
GAL 101 (formerly MRZ 99030 or EG-030) a small-molecule β-amyloid (Aβ) aggregation modulator with neuroprotective activity. It does not directly prevent early protein/protein interactions between monomeric Aβ, but rather promotes the formation of large, non-amyloidogenic, amorphous Aβ aggregates and thereby reduces the amount of intermediate toxic soluble oligomeric Aβ species. In vivo studies demonstrate the neuroprotective potential of MRZ-99030 after systemic and topical administration in animal models of Alzheimer's disease and glaucoma and age-related macular degeneration respectively. Currently, it is in Phase I trial for the treatment of glaucoma.
Originator
Approval Year
Sample Use Guides
In anaesthetized rats, pre-administration of MRZ-99030 (50 mg/kg s.c.) protected against deficits in hippocampal LTP following i.c.v. injection of oligomeric Aβ1-42.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2OZL368FU0
Created by
admin on Sat Dec 16 12:07:05 GMT 2023 , Edited by admin on Sat Dec 16 12:07:05 GMT 2023
|
PRIMARY | |||
|
56649444
Created by
admin on Sat Dec 16 12:07:05 GMT 2023 , Edited by admin on Sat Dec 16 12:07:05 GMT 2023
|
PRIMARY | |||
|
1123071-24-8
Created by
admin on Sat Dec 16 12:07:05 GMT 2023 , Edited by admin on Sat Dec 16 12:07:05 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
